Loading...

APC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_APC_041106
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
  • 53-6dot7_APC_041106
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
100711 25 µg 27€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100712 100 µg 84€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Choi JG, et al. 2020. Front Immunol. 11:598556. PubMed
  2. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  3. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  4. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  5. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  6. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  7. Li X et al. 2019. Immunity. 50(3):576-590 . PubMed
  8. O'Malley G, et al. 2018. Cancer Immunol Res. 1.240277778. PubMed
  9. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  10. Xu X, et al. 2020. Chin Med. 15:33. PubMed
  11. Puth S, et al. 2022. Biomaterials. 286:121542. PubMed
  12. Guo A, et al. 2022. Nature. 607:135. PubMed
  13. Chen R, et al. 2022. J Mol Cell Biol. 14:. PubMed
  14. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  15. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  16. Pagni RL, et al. 2022. Front Immunol. 13:1005937. PubMed
  17. Chen H, et al. 2023. Nat Commun. 14:941. PubMed
  18. Li X, et al. 2023. J Clin Invest. 133:. PubMed
  19. Kozlovski S, et al. 2023. Front Immunol. 13:1041552. PubMed
  20. Saha S, et al. 2023. Sci Rep. 13:4609. PubMed
  21. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  22. Shi Y, et al. 2023. Nat Commun. 14:1884. PubMed
  23. Huang T, et al. 2023. Front Immunol. 14:1124152. PubMed
  24. Wu N, et al. 2023. Front Bioeng Biotechnol. 11:1173381. PubMed
  25. Zhang YT, et al. 2023. Front Immunol. 14:1085456. PubMed
  26. Zhang J, et al. 2023. Theranostics. 13:2226. PubMed
  27. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  28. He Y, et al. 2023. Biomolecules. 13:. PubMed
  29. Deng G, et al. 2023. Cancers (Basel). 15:. PubMed
  30. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  31. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  32. Wang D, et al. 2023. Nat Commun. 14:2943. PubMed
  33. Li M, et al. 2023. BMC Cancer. 23:497. PubMed
  34. Zeng S, et al. 2023. Front Oncol. 13:1171926. PubMed
  35. Lan Y, et al. 2023. iScience. 26:106817. PubMed
  36. Zhang AQ, et al. 2023. Nat Biomed Eng. . PubMed
  37. Song S, et al. 2023. Bioact Mater. 28:358. PubMed
  38. Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed
  39. Thomas R, et al. 2021. Immunology. 163:478. PubMed
  40. Zhou Y, et al. 2021. Methods Mol Biol. 2388:35. PubMed
  41. Schenkel JM, et al. 2021. Immunity. 54:2338. PubMed
  42. Kragten NAM, et al. 2022. Eur J Immunol. 52:389. PubMed
  43. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  44. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  45. Yue Y, et al. 2022. Nat Biomed Eng. 6:898. PubMed
  46. Aghayev T, et al. 2022. Cancer Discov. 12:1960. PubMed
  47. Zhao Z, et al. 2022. Adv Sci (Weinh). 9:e2201293. PubMed
  48. Blanco LP, et al. 2022. Arthritis Rheumatol. 74:1971. PubMed
  49. Marié IJ, et al. 2022. Bio Protoc. 12:e4438. PubMed
  50. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  51. Xie DH, et al. 2022. Med Phys. 49:6728. PubMed
  52. Chen Y, et al. 2023. Adv Healthc Mater. 12:e2202085. PubMed
  53. Theofilatos D, et al. 2022. STAR Protoc. 3:101839. PubMed
  54. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  55. You Q, et al. 2023. Adv Mater. 35:e2204910. PubMed
  56. Yu J, et al. 2022. Nat Commun. 13:7903. PubMed
  57. Morrow RJ, et al. 2022. Cells. 11: . PubMed
  58. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  59. Ding D, et al. 2023. J Med Chem. 66:1467. PubMed
  60. Lin J, et al. 2023. Nat Commun. 14:224. PubMed
  61. Smith LA, et al. 2023. Front Oncol. 12:1031174. PubMed
  62. Ali LR, et al. 2023. J Exp Med. 220: . PubMed
  63. Kasuya T, et al. 2023. Sci Rep. 13:1653. PubMed
  64. Wang R, et al. 2023. NPJ Vaccines. 8:6. PubMed
  65. Meng S, et al. 2023. Stem Cell Investig. 10:2. PubMed
  66. Zheng J, et al. 2023. Biomater Res. 27:9. PubMed
  67. Zhao M, et al. 2023. J Nanobiotechnology. 21:50. PubMed
  68. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  69. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
  70. Mise Y, et al. 2022. Carcinogenesis. 43:647. PubMed
  71. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  72. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  73. Renrick AN, et al. 2021. Front Immunol. 607044:12. PubMed
  74. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
  75. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  76. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  77. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  78. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  79. Zhao X, et al. 2022. Front Mol Biosci. 9:786864. PubMed
  80. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  81. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  82. Ma Z, et al. 2016. Clin Cancer Res. 22: 2969 - 2980. PubMed
  83. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  84. Leach SM, et al. 2020. Cell Rep. 33:108337. PubMed
  85. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  86. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  87. Dong L, et al. 2021. Cancer Cell. . PubMed
  88. Castiello MC, et al. 2020. J Allergy Clin Immunol. . PubMed
  89. Wang D, et al. 2018. Immunity. 48:659. PubMed
  90. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  91. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  92. Takeda Y, et al. 2018. Innate Immun. 24:323. PubMed
  93. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  94. Riley JS, et al. 2020. Blood Adv. 4:1102. PubMed
  95. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
  96. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  97. Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed
  98. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  99. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
  100. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  101. Li ZX, et al. 2022. Arch Virol. :. PubMed
  102. Ghosh S, et al. 2022. APL Bioeng. 6:036105. PubMed
  103. Bauer KM, et al. 2022. JCI Insight. 7:. PubMed
  104. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  105. Hirano KI, et al. 2021. eLife. 0.416666666666667. PubMed
  106. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  107. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  108. Blumenthal D, et al. 2020. eLife. 9:e55995.. PubMed
  109. Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed
  110. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  111. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  112. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  113. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  114. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  115. Tian H, et al. 2022. Cancer Sci. 113:875. PubMed
  116. Zhao J, et al. 2022. J Nanobiotechnology. 20:62. PubMed
  117. Felker A, Croy B 2016. J Leukoc Biol. 100: 645 - 655. PubMed
  118. Wagner V, et al. 2016. Sci Transl Med. 8: 366ra164. PubMed
  119. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  120. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  121. Chen S et al. 2018. Cell reports. 25(7):1729-1740 . PubMed
  122. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  123. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  124. Zhang F, et al. 2019. Nat Commun. 10:3974. PubMed
  125. Lee JH, et al. 2018. Transgenic Res. 27:241. PubMed
  126. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  127. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  128. Yin Y, et al. 2021. ACS Nano. 15:14347. PubMed
  129. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  130. Zhan CS, et al. 2020. FASEB J. 14006:34. PubMed
  131. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  132. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  133. Lebratti T, et al. 2021. eLife. 10:00. PubMed
  134. Eriksson E, et al. 2016. Gene Ther. 10.1038/gt.2016.80. PubMed
  135. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  136. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  137. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  138. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  139. Li Y, et al. 2019. Oncol Rep. 41:2679. PubMed
  140. Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed
  141. Guo H, et al. 2022. PLoS Pathog. 18:e1010857. PubMed
  142. Frey N, et al. 2022. Nat Commun. 13:1804. PubMed
  143. Zhang J, et al. 2022. Front Immunol. 13:931740. PubMed
  144. Bhattacharya P, et al. 2022. PLoS Negl Trop Dis. 16:e0010224. PubMed
  145. Zhan Y, et al. 2021. JCI Insight. 6:. PubMed
  146. Yin Q, et al. 2015. PLoS One. 10: 0137808. PubMed
  147. Vieyra-Garcia P, et al. 2016. Clin Cancer Res. 22: 3328 - 3339. PubMed
  148. Matsumura K, et al. 2016. J Immunol. 197: 3233 - 3244. PubMed
  149. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  150. Solanki A, et al. 2018. Development. 145. PubMed
  151. Koliaraki V et al. 2019. Cell reports. 26(3):536-545 . PubMed
  152. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  153. Riffelmacher T et al. 2017. Immunity. 47(3):466-480 . PubMed
  154. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  155. Wang L, et al. 2021. Cancer Immunol Res. 9:348. PubMed
  156. Si L, et al. 2022. Nat Biotechnol. 40:1370. PubMed
  157. Ebina-Shibuya R, et al. 2021. Elife. 10:. PubMed
  158. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  159. Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed
  160. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  161. Brummer G, et al. 2020. Oncogene. 39:2275. PubMed
  162. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  163. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  164. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  165. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  166. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  167. Liu J, et al. 2019. J Exp Med. 216:656. PubMed
  168. Funk KE, et al. 2019. J Neuroinflammation. 16:22. PubMed
  169. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  170. Divan A, et al. 2018. PLoS One. 13:e0196893. PubMed
  171. He X, et al. 2021. Small. 17:e2007165. PubMed
  172. Pervaiz N, et al. 2021. Pigment Cell Melanoma Res. 34:918. PubMed
  173. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  174. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  175. Jeong SH, et al. 2021. Nat Commun. 12:4405. PubMed
  176. Chen Q, et al. 2016. Nat Commun. 7:13193. PubMed
  177. Hoefflin R, et al. 2020. Nat Commun. 3.313194444. PubMed
  178. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  179. Lee JS et al. 2018. Cell. 174(6):1559-1570 . PubMed
  180. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  181. Zheng Z, et al. 2020. Cell Death Dis. 0.684722222. PubMed
  182. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  183. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  184. Tartey S, et al. 2021. Cancer Research. 81(9):2358-2372. PubMed
  185. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
  186. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  187. Yi X, et al. 2020. Sci Adv. 6:eaba3546. PubMed
  188. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  189. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  190. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  191. Bai C, et al. 2020. Mol Ther Oncolytics. 17:9. PubMed
  192. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
  193. Al–Zaher AA, et al. 2018. Mol Ther Oncolytics. 0.376388889. PubMed
  194. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  195. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  196. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  197. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  198. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  199. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  200. Liu T, et al. 2022. Front Immunol. 13:901349. PubMed
  201. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  202. Goldfarb Y, et al. 2021. J Exp Med. 218:. PubMed
  203. Ye P, et al. 2022. Front Cardiovasc Med. 8:810477. PubMed
  204. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  205. Gibbins J, et al. 2014. Blood. 124:2953. PubMed
  206. Ku C, et al. 2015. Genes Dev. 29: 1930-1941. PubMed
  207. Cook KD, et al. 2015. Immunity. 43:703-714. PubMed
  208. Latasa C, et al. 2016. PLoS One. 11: 0161216. PubMed
  209. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  210. Wanner-Seleznik GM, et al. 2020. Immunohorizons. 0.644444444. PubMed
  211. Zeng W, et al. 2021. STAR Protocols. 2(1):100361. PubMed
  212. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  213. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  214. Hu J, et al. 2019. Mol Ther Nucleic Acids. 16:650. PubMed
  215. Matsuo K, et al. 2018. J Immunol. 200:800. PubMed
  216. Takaku S, et al. 2020. Integr Cancer Ther. 19:1534735419900798. PubMed
  217. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  218. Medyouf H, et al. 2010. Blood. 115:1175. PubMed
  219. Oka Y, et al. 2020. Sci Adv. 6:. PubMed
  220. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  221. Jiang Y, et al. 2020. Adv Mater. 32:e2001808. PubMed
  222. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  223. Li H, et al. 2021. Nat Commun. 12:7149. PubMed
  224. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  225. Wu H, et al. 2021. Cell Death Discov. 7:225. PubMed
  226. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  227. Zhang Q, et al. 2022. Nat Commun. 13:2406. PubMed
  228. Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed
  229. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  230. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  231. Oguri Y, et al. 2020. Cell. 182(3):563-577.e20. PubMed
  232. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  233. Lin W, et al. 2019. EBioMedicine. 49:133. PubMed
  234. Chen Z, et al. 2019. J Exp Med. 216:152. PubMed
  235. Nam GH, et al. 2018. Nat Commun. 9:2165. PubMed
  236. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  237. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  238. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  239. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  240. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  241. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  242. Sun S, et al. 2013. J Immunol. 190:6209. PubMed
  243. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  244. Nanou A, et al. 2021. Cell Reports. 35(8):109168. PubMed
  245. Lin YH, et al. 2018. Cancer Immunol Res. 0.25. PubMed
  246. Morelli AE, et al. 2020. Cell Rep. 30:3448. PubMed
  247. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  248. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  249. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  250. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
  251. Feng Y, et al. 2022. J Nanobiotechnology. 20:193. PubMed
  252. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  253. Alexandre YO, et al. 2020. Cell Reports. 33(13):108567. PubMed
  254. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  255. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  256. Wu L, et al. 2020. Cell Rep. 33:108327. PubMed
  257. Swanson P, et al. 2016. PLoS Pathog. 12:e1006022. PubMed
  258. Teo T, et al. 2015. J Virol. 89: 7955-7969. PubMed
  259. Sasaki Y, et al. 2015. PLoS One. 10: 0131176. PubMed
  260. Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed
  261. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  262. Takahashi F, et al. 2022. iScience. 25:104278. PubMed
  263. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  264. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  265. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  266. Li X, et al. 2021. Cell Death Dis. 12:314. PubMed
  267. Frazer GL, et al. 2021. J Cell Biol. 220:. PubMed
  268. Do-Thi VA, et al. 2021. Cancers (Basel). 13:. PubMed
  269. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  270. Kataru RP, et al. 2022. Front Aging. 3:864860. PubMed
  271. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  272. Huber MK, et al. 2021. J Vis Exp. :. PubMed
  273. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  274. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
  275. Ulaganathan VK, et al. 2020. Sci Rep. 10:8453. PubMed
  276. Li X, et al. 2017. Front Immunol. 8:1186. PubMed
  277. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  278. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  279. Fonderflick L, et al. 2022. Cells. 11:. PubMed
  280. Rao L, et al. 2020. Nat Commun. 11:4909. PubMed
  281. Murata T, et al. 2020. Sci Rep. 10:13560. PubMed
  282. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  283. Zheng Z, et al. 2021. Nat Commun. 12:6202. PubMed
  284. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  285. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  286. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  287. Zheng DW, et al. 2020. Nat Commun. 3.865972222. PubMed
  288. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  289. Lu C, et al. 2020. Cancer Cell. 39(1):96-108.e6. PubMed
  290. Gaya M et al. 2018. Cell. 172(3):517-533 . PubMed
  291. Zhang J, et al. 2018. Oncoimmunology. 7:e1461301. PubMed
  292. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  293. Chao Y, et al. 2020. Sci Adv. 6:eaaz4204. PubMed
  294. Kataru RP, et al. 2019. Cancer Immunol Res. 7:1345. PubMed
  295. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  296. Zheng Z, et al. 2021. Biomed Res Int. 2021:5535578. PubMed
  297. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  298. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  299. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  300. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  301. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  302. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  303. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  304. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  305. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  306. Tippimanchai DD, et al. 2018. Oncoimmunology. 7:e1438105. PubMed
  307. Liu YW, et al. 2022. JCI Insight. 7:. PubMed
  308. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  309. Chen B, et al. 2021. Cell. 184:6262. PubMed
  310. Smith LK, et al. 2021. Elife. 10:. PubMed
  311. Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed
  312. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  313. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  314. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  315. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  316. Cong L, et al. 2021. Breast Cancer Res. 23:51. PubMed
  317. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  318. Zhou P, et al. 2022. Mol Ther Oncolytics. 25:236. PubMed
  319. Zheng Y, et al. 2022. Transl Res. :. PubMed
  320. Funk KE, et al. 2021. Aging Cell. 20:e13412. PubMed
  321. Galeano Nio JL, et al. 2020. eLife. 9:00. PubMed
  322. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  323. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
  324. Zhang Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  325. Bessell CA, et al. 2020. JCI Insight. 5:. PubMed
  326. Li C, et al. 2022. Front Cell Dev Biol. 10:913824. PubMed
  327. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  328. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
RRID
AB_312750 (BioLegend Cat. No. 100711)
AB_312751 (BioLegend Cat. No. 100712)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01.21.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account